5. 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

OCT 1 9 2012

The assigned 510(k) number is: K112605

1 C-1-144-3 b	Common America Tra
1. Submitted by:	Sysmex America, Inc. One Nelson C. White Parkway
	Mundelein, IL. 60060
	·
	Phone: (847) 996-4618; FAX: (847) 996-4655
	Contact person: Sharita Brooks
4 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	Date prepared: August 31, 2011
2. Name of Device:	Trade or proprietary name: Sysmex® XN-Series (XN-10, XN-20)
	Common name: Automated Hematology Analyzer
	Classification name: Automated Differential Cell Counter 21 CFR 864.5220 is a
	Class II device. Product Code: GKZ
	Related Items:
	Deschart Codes Of CIE
	Product Code: 81GIF CELLPACK TM DCL (Diluent)
	CELLPACK DCL (Diluent) CELLPACK DCL (Diluent)
	CELLPACK DFL (Diluent)
	Product Code: 81GGK
	LYSERCELL WNR (Lyse)
	LYSERCELL WDF (Lyse)
	LYSERCELL WPC (Lyse)
	LISERCELL WPC (Lyse)
	Product Code: 81KJK
	FLUOROCELL WNR (Stain)
	FLUOROCELL WDF (Stain)
,	FLUOROCELL RET (Stain)
•	FLUOROCELL PLT (Stain)
	FLUOROCELL WPC (Stain)
	Product Code: 81KSA
	XN CAL (Calibrator)
	XN CAL PF (Calibrator)
	Product Code: 91 IDV
	Product Code: 81JPK XN-Check (Control)
,	
	XN-Check BF (Control)
	Analyzer Components
	SA-10 (Auto Sampler for single module)
	SA-20 (Auto Sampler for two modules)
	IPU (Information Processing Unit)
3. Predicate Device:	Sysmex® XE-5000Automated Hematology Analyzer

A Davige Descriptions	The Symmer (N VN Series modules (VN 10 VN 20) are multi-necessary
4. Device Description:	The Sysmex® XN-Series modules (XN-10, XN-20) are multi-parameter hematology
	analyzers intended to perform tests on whole blood samples collected in K ₂ or
	K ₃ EDTA and body fluids (pleural, peritoneal and synovial) collected in K ₂
	anticoagulant. It can also perform tests on CSF which should not be collected in any
	anticoagulant. The instrument consists of four principal units: (1) Two Main Units
	(XN-10, XN-20) which aspirate, dilute, mix, and analyze blood and body fluid
	samples; (2) Two Auto Sampler Units (SA-10, SA-20) which supply samples to the
	Main Unit automatically; (3) IPU (Information Processing Unit) which processes
	data from the Main Unit and provides the operator interface with the system; (4) Pneumatic Unit which supplies pressure and vacuum from the Main Unit. The XN-
	Series analyzers perform analysis using the following methods: RF/DC Detection
	Method, Sheath Flow DC Detection Method, and Flow Cytometry Methods using a
	Semiconductor Laser. Particle characterization and identification is based on
	detection of forward scatter, fluorescence and adaptive cluster analysis. The XN-
	Series analyzers automatically classify cells from whole blood and body fluids and
	carry out all processes automatically from aspiration of the sample to outputting the
	results.
	100410.
	The body fluid analysis mode of the XN-Series analyzers uses the 4DIFF
·	scattergram & the RBC distribution obtained from a specialized analysis sequence to
	calculate & display the WBC (WBC-BF) counts, mononuclear cell (MN) /
	polymorphonuclear cell (PMN) counts & percentages, TC-BF (Total Count) & RBC
	(RBC-BF) counts found in the body fluid.
	Analysis results and graphics are displayed on the IPU screen. They can be printed
	on any of the available printers or transmitted to a Host computer.
5. Intended Use:	
	The XN-Series modules (XN-10, XN-20) are quantitative multi-parameter
	automated hematology analyzers intended for <i>in vitro</i> diagnostic use in screening patient populations found in clinical laboratories.
	The XN-Series modules classify and enumerate the following parameters in whole
	blood: WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT (PLT-I, PLT-F),
	NEUT%/#, LYMPH%/#, MONO%/#, EO%/#, BASO%/#, IG%/#, RDW-CV,
	RDW-SD, MPV, NRBC#/%, RET%/#, IPF, IRF, RET-He and has a Body Fluid
	mode for body fluids. The Body Fluid mode enumerates the WBC-BF, RBC-BF,
	MN%/#, PMN%/#, and TC-BF parameters in cerebrospinal fluid (CSF), serous
	fluids (peritoneal, pleural) and synovial fluids. Whole blood should be collected in K_2 or K_3 EDTA anticoagulant and, Serous and Synovial fluids in K_2 EDTA
	anticoagulant to prevent clotting of fluid. The use of anticoagulants with CSF
	specimens is neither required nor recommended.
6. Substantial equivalence-	The following table compares the XN-Series modules (XN-10, XN-20) Automated
similarities and differences	Hematology analyzers with the XE-5000 Automated Hematology analyzer.
7. Clinical Performance	Studies were performed to evaluate the equivalency of the XN-Series Automated
Data:	Hematology analyzers (Modules XN-10, XN-20) to the XE-5000 Automated
	Hematology analyzer. Results indicated equivalent performance.
8. Conclusions:	The performance data demonstrated substantial equivalence.

Table 1: Substantial Equivalence – Similarities and Differences to the XN-Series Automated Hematology analyzers (Modules XN-10, XN-20) and XE-5000 Automated Hematology analyzer.

Features 52	Predicate XE-5000	FF XXN	Series File
(Submission #)	(K071967)	Experience (XN-10),XN-20)
FDA Clearance	20-Nov-07		
Intended Use	XE-5000	XN-10	XN-20
	Sysmex® XE-5000 is an	The Sysmex® XN-10	The Sysmex® XN-20 module is
	automated hematology	module is a quantitative	a quantitative multi-parameter
	analyzer for in vitro	multi-parameter automated	automated hematology analyzer
II.	diagnostic use in screening	hematology analyzer	intended for in vitro diagnostic
	patient populations found in	intended for in vitro	use in screening patient
	clinical laboratories. The	diagnostic use in screening	populations found in clinical
	XE-5000 classifies and	patient populations found in	laboratories. The XN-Series
	enumerates the same	clinical laboratories. The	modules classify and enumerate
	parameters as the XE-2100	XN-Series modules classify	the following parameters in
	using whole blood as	and enumerate the following	whole blood: WBC, RBC,
İ	described below, cord blood	parameters in whole blood:	HGB, HCT, MCV, MCH, MCHC, PLT (PLT-I, PLT-F),
	for HPC and has a body fluid mode for body fluids. The	WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT	NEUT%/#, LYMPH%/#,
1	Body Fluid mode analyzes	(PLT-I, PLT-F), NEUT%/#,	MONO%/#, E0%/#,
!	WBC-BF, RBC-BF,	LYMPH%/#, MONO%/#,	BASO%/#, IG%/#, RDW-CV,
4	MN%/#, PMN%/# and TC-	E0%/#, BASO%/#, IG%/#,	RDW-SD, MPV, NRBC#/%,
	BF in body fluids	RDW-CV, RDW-SD, MPV,	RET%/#, IPF, IRF, RET-He
	(cerebrospinal fluids (CSF),	NRBC#/%, RET%/#, IPF,	and has a Body Fluid mode for
	serous fluids, and synovial	IRF, RET-He and has a Body	body fluids. The Body Fluid
	fluids with EDTA, as	Fluid mode for body fluids.	mode enumerates the WBC-BF,
	needed).	The Body Fluid mode	RBC-BF, MN%/#, PMN%/#,
	WBC, RBC, HGB, HCT,	enumerates the WBC-BF,	and TC-BF parameters in
•	MCV, MCH, MCHC, PLT,	RBC-BF, MN%/#, PMN%/#,	cerebrospinal fluid (CSF),
	NEUT% / #, LYMPH% / #,	and TC-BF parameters in	serous fluids (peritoneal,
	MONO% / #, EO% / #,	cerebrospinal fluid (CSF),	pleural) and synovial fluids.
	BASO% / #, NRBC% / #,	serous fluids (peritoneal,	Whole blood should be
	RDW-SD, RDW-CV, MPV,	pleural) and synovial fluids.	collected in K₂ or K₃EDTA
	RET% / #, IRF, IG% / #,	Whole blood should be	anticoagulant and, Serous and
	RET-He, IPF, HPC	collected in K2 or K3EDTA	Synovial fluids in K ₂ EDTA
	WBC-BF, RBC-BF,	anticoagulant and, Serous	anticoagulant to prevent clotting
	MN% / #, PMN%/ #, TC-BF#.	and Synovial fluids in	of fluid. The use of
	10-Br#.	K₂EDTA anticoagulant to	anticoagulants with CSF specimens is neither required
		prevent clotting of fluid. The use of anticoagulants with	nor recommended.
		CSF specimens is neither	nor recommended.
		required nor recommended.	
	SECTION SECTION OF THE SECTION OF TH	MILARITIES	
Sample Type	Whole blood	Whole Blood	Whole Blood
	Body Fluids	Body Fluids	Body Fluids
	-	-	-
Principles	Performs hematology	-	
-	analyses according to the		
	Hydro Dynamic Focusing	SAME	SAME
	(DC Detection), flow		
	cytometry method (using a		ļ
	semiconductor laser), and		

Sysmex XN-Series modules (XN-10, XN-20) Automated Hematology Analyzers 510(k) Submission

	SLS-hemoglobin method.		
Parameters	Whole Blood Mode: WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT, NEUT%/#, LYMPH%/#, MONO%/#, EO%/#, BASO%/#, NRBC%/#, RDW-CV, RDW-SD, MPV, RET%/#, IRF, IG%/#, RET- He#, IPF. Body Fluid Mode: WBC-BF, RBC-BF, MN%/#, PMN%/#, TC-BF#	Whole Blood Mode: WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT (PLT-I, PLT-F), NEUT%/#, LYMPH%/#, MONO%/#, EO%/#, BASO%/#, NRBC%/#, RDW-CV, RDW-SD, MPV, RET%/#, IRF, IG%/#, RET-He#, IPF. Body Fluid Mode: WBC-BF, RBC-BF, MN%/#, PMN%/#, TC-BF#	Whole Blood Mode: WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT (PLT-I, PLT-F), NEUT%/#, LYMPH%/#, MONO%/#, EO%/#, BASO%/#, NRBC%/#, RDW-CV, RDW-SD, MPV, RET%/#, IRF, IG%/#, RET- He#, IPF. Body Fluid Mode: WBC-BF, RBC-BF, MN%/#, PMN%/#, TC-BF#
Reagents	SULFOLYSER (Lyse)	SAME	SAME
Principles	Performs hematology analysis according to the RF/DC detection method, Hydro Dynamic Focusing (DC Detection), flow cytometry method (using a semiconductor laser), and SLS hemoglobin method.	SAME	SAME
Modes of Operation	Sampler Analysis Mode Manual Closed Analysis Mode Body Fluid Analysis Mode	SAME	SAME
Measuring Channels	RET/PLT	SAME	SAME
Equivalency Data	Proven performance in FDA submission	Data consisting of Accuracy, Precision, Linearity and Carryover were collected to show performance to the manufacturer's specification for the Body Fluid mode. This analysis supports the claim that the XN-10 analyzer is substantially equivalent to the XE-5000.	Data consisting of Accuracy, Precision, Linearity and Carryover were collected to show performance to the manufacturer's specification for the Body Fluid mode. This analysis supports the claim that the XN-20 analyzer is substantially equivalent to the XE-5000.
	DI	GERENCES:	
Item	Predicate XE-5000 (K071967)	XN-Series (XN-10, XN-20)	
Controls & Calibrators	• Whole Blood • e-Check (XE) – 3 Levels Whole Blood Stability Unopened 84 days XE Calibrator	*XN-10 Whole Blood *XN-Check - 3 Levels Whole Blood Stability Unopened 84 days *XN-10 Calibrator	XN-20 Whole Blood *XN-Check - 3 Levels Whole Blood Stability Unopened 84 days *XN-20 Calibrator

	(X CAL)	(XN CAL)	(XN CAL)
	Not Available	Platelet F Calibrator (XN CAL PF)	Platelet F Calibrator (XN CAL PF)
	Not Available	Body Fluid XN Check BF - 2 Levels *Product name change only.	Body Fluid XN Check BF - 2 Levels *Product name change only.
IPU	Single Module connect	Multi-Module connect	Multi-Module connect
Modes of Operation	Manual Open Cap Analysis Mode (Operator presents sample to aspiration needle)	Manual Open Cap Analysis Mode (Sample placed in tube holder position)	Manual Open Cap Analysis Mode (Sample placed in tube holder position)
	Capillary Analysis Mode Dilute sample 1:5	Pre-dilute Analysis Mode Dilute sample 1:7	Pre-dilute Analysis Mode Dilute sample 1:7
	Not Available	Low WBC Mode (LWBC)	Low WBC Mode (LWBC)
Sample Type	Umbilical Cord Blood	Not Available	Not Available
Parameters	HPC	Not Available	Not Available
Sample Aspiration	mrc .	Not Available	Not Available
/Fluidic Pathway	Two pathways	Single pathway	Single pathway
Dimensions of Main		Width: 645mm	Width: 645mm
Unit (Including	Width: 706mm	Height: 855mm	Height: 855mm
Sampler Unit)	Height: 711mm	Depth: 755mm	Depth: 755mm
Weight (Ira)	Depth: 912mm 93	(Single Unit)	(Single Unit)
Weight (kg) Including Sampler	(Single Unit)	(Single Unit)	(Single Unit)
Software/Hardware	No Rules-based rerun /	Rules-based rerun / reflex	Rules-based rerun / reflex
Throughput	Whole Blood Approximately 113-150 depending on mode used.	Whole Blood 100 samples/hour maximum depending on mode used.	Whole Blood 100 samples/hour maximum depending on mode used.
	Body Fluid 38 samples/hour	Body Fluid 40 samples/hour maximum	Body Fluid 40 samples/hour maximum
Measuring Channels	WBC/BASO	WNR	WNR
(see Section 11 for	DIFF	WDF	WDF
detailed information	NRBC	WNR	WNR
on these channels)	IMI Not Available	Not Available PLT-F	WPC PLT-F
Reagents		CELLPACK TM DCL	CELLPACK TM DCL (Diluent)
Acagento	CELLPACK TM (Diluent) CELLSHEATH TM (Diluent)	(Diluent)	CELLPACK DCL (Diluent)
	STROMATOLYSER-FB TM	CELLPACK [™] DFL	LYSERCELL WNR (Lyse)

			,
	(Lyse)	(Diluent)	LYSERCELL WDF (Lyse)
	STROMATOLYSER-	LYSERCELL WNR	FLUOROCELL WNR (Stain)
	4DL TM (Lyse)	(Lyse)	FLUOROCELL WDF (Stain)
	STROMATOLYSER-	LYSERCELL WDF	FLUOROCELL RET (Stain)
	4DS TM (Stain)	(Lyse)	FLUOROCELL PLT (Stain)
	STROMATOLYSER-NR TM	FLUOROCELL WNR	
	(Diluent)	(Stain)	LYSERCELL WPC (Lyse)
	STROMATOLYSER-NR TM	FLUOROCELL WDF	FLUOROCELL WPC (Stain)
	(Stain)	(Stain)	·
	RET-SEARCH II (Diluent)	FLUOROCELL RET	
	RET-SEARCH II (Stain)	(Stain)	
	STROMATOLYSER-	FLUOROCELL PLT	
	IM TM (Lyse)	(Stain)	
Sample Aspiration	Sampler Mode – 200µL	Sampler Mode – 88µL	Sampler Mode – 88μL
Volume	Manual (Closed Cap) Mode	Manual (Closed Cap)	Manual (Closed Cap) Mode -
	- 200μL	Mode - 88µL	88μL
	Manual (Open Cap) Mode -	Manual (Open Cap) Mode	Manual (Open Cap) Mode -
	130µL	- 88µL	88μL
	Capillary Mode - 130µL	Dilution Mode - 70µL	Dilution Mode - 70μL
	Body Fluid Mode - 130µL	Body Fluid Mode - 88µL	Body Fluid Mode - 88µL



10903 New Hampshire Avenue Silver Spring, MD 20993

OCT 1 9 2012

Sysmex America, Inc. c/o Ms. Sharita Brooks Clinical Affairs Specialist II 577 Aptakisic Road Lincolnshire, IL 60069

Re: k112605

Trade/Device Name: Sysmex® XN-Series (XN-10, XN-20) Automated Hematology

Analyzers

Regulation Number: 21 CFR § 864.5220

Regulation Name: Automated differential cell counter

Regulatory Class: Class II Product Code: GKZ

Dated: October 15, 2012 Received: October 16, 2012

Dear Ms. Brooks:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice

Page 2 – Ms. Sharita Brooks

requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in you Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostics and Radiological Health at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Maria M. Chan, Ph.D

Director

Division Immunology and Hematology Devices Office of *In Vitro* Diagnostics and Radiological Health Center for Devices and Radiological Health

maria on chan

Enclosure

4. INDICATIONS FOR USE STATEMENT

510(k) Number (if known)k	<u> </u>
Device Name: XN-Series (XN-10,	XN-20) Automated Hematology Analyzers
Indications for Use:	
	20) are quantitative multi-parameter automated hematology stic use in screening patient populations found in clinical
HGB, HCT, MCV, MCH, MCHC, PL BASO%/#, IG%/#, RDW-CV, RDW-Fluid mode for body fluids. The Body PMN%/#, and TC-BF parameters in cosynovial fluids. Whole blood should be	enumerate the following parameters in whole blood: WBC, RBC, T (PLT-I, PLT-F), NEUT%/#, LYMPH%/#, MONO%/#, EO%/#, SD, MPV, NRBC#/%, RET%/#, IPF, IRF, RET-He and has a Body of Fluid mode enumerates the WBC-BF, RBC-BF, MN%/#, erebrospinal fluid (CSF), serous fluids (peritoneal, pleural) and be collected in K ₂ or K ₃ EDTA anticoagulant and, Serous and lant to prevent clotting of fluid. The use of anticoagulants with recommended.
	•
	·
	; · · · ; · · · ; · · · · ; · · · · · ·
Prescription Use X (Part 21 CFR 801 Subpart D)	AND/OR Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASÉ DO NOT WRITE BELOW	THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDR	H, Office of In Vitro Diagnostic Devices (QIVD)
	Division Sign-Off
Sysmex XN-Series modules (XN-10, XN-2 Automated Hematology Analyzers 510(k)	20)

Office of in Vitro Diagnostic
Device Evaluation and Safety